Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.63 -0.02 (-0.01%) 5:20 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$160.65 USD
+0.96 (0.60%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $160.63 -0.02 (-0.01%) 5:20 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
5 Drug Stocks for Your Portfolio this World Health Day
by Arpita Dutt
With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.
AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
by Zacks Equity Research
Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
by Zacks Equity Research
We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.
AT&T & Verizon Suspend Marketing Advertisements from YouTube
by Zacks Equity Research
AT&T Inc. (T) and Verizon Communications Inc. (VZ) have decided to suspend their marketing campaign on Google's YouTube site.
5 Excellent ETFs for Your IRA
by Neena Mishra
Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
by Arpita Dutt
Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
by Zacks Equity Research
Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate
Large Cap ETF (IVV) Tops $100 billion in AUM
by Sweta Killa
IVV is the second ETF in the space that has managed to garner $100 billion in AUM after SPY.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage
J&J Presents Positive Phase III Data on Psoriasis Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.
by Zacks Equity Research
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.
Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao
by Swarup Gupta
The Dow notched up a record streak of gains over a holiday shortened week.
Johnson & Johnson (JNJ) Up 6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
by Zacks Equity Research
Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.
4 Drug Stocks that are Broker Favorites
by Arpita Dutt
Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.